Genetic drivers of ovarian cancer development - Dr. Leary
Comparison of pharmacologic properties of approved PARP inhibitors - Dr. Marmé
PARP inhibitor-related adverse event identification and management – Dr. Ledermann
Live attendee Q&A
Date / Time
Jonathan Ledermann, MD, FRCP, FMed Sci
Professor of Medical Oncology,
CRUK and UCL Cancer Trials Centre,
UCL Cancer Institute, London UK
Alexandra Leary, MD, PhD
Medical Oncologist and Team Leader, Gynecology Translational Research Lab,
Department of Medicine,
Gustave Roussy Cancer Center,
Frederik Marmé, MD PhD
Assistant Professor of Gynecology,
Medical Faculty of Heidelberg,
University of Heidelberg, Germany
The goal of this activity is to improve global learners’ knowledge and competence in applying practice-changing clinical data and expert recommendations to optimize the use of PARP inhibitors for the treatment of patients with ovarian cancer.
This program is intended for global gynecologic oncologists, medical oncologists, and other healthcare providers who care for patients with ovarian cancer.
Upon completion of this activity, participants should be able to:
- Assess recent clinical data on the safety and efficacy of PARP inhibitors for the frontline treatment of ovarian cancer
- Recognize PARP inhibitor–related toxicities and define supportive management strategies to minimize these adverse events
- Discuss ongoing clinical research evaluating the role of PARP inhibitors in combination with chemotherapy, targeted therapy, and immunotherapy as frontline therapy for ovarian cancer to aid referral for clinical trial participation
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.